PAEAN Biotechnology

PAEAN Biotechnology Inc. is a biotech company focusing on development, license-out, and commercialization of mitochondria-based first-in-class pharmaceuticals to treat incurable diseases. Since early 2017, PAEAN has been developing anti-inflammatory and anti-cancer biopharmaceuticals based on mitochondria isolated from stem cells. Main pipelines include: 1. Mitochondria Therapeutics (PN-101, PN-102) utilize isolated mitochondria from cultured stem cells to treat Polymyositis and Sepsis (transfer of mitochondria effectively relieves inflammation); 2. Mitochondrial Cell Therapeutics (PN-201, PN-202) include mitochondria enriched cell therapy products (NK and stem cells) to treat cancer or mitochondria dysfunctioned diseases; 3. Protein Therapeutics (PN-30X) include a next-generation innovative precision medicine which cincept is similar to ADC. To deliver a protein into cells and to target it the specific cells, recombinant proteins such as P53 and scFv are combined with mitochondria to create a "modified" mitochondria complex targeting and killing the cancer cells. PAEAN's unique approach toward disease treatment had successfully secured Series-A investment in 2019 and expects to received the Series-B funding for clinical studies and set-up of mitochondria production facilities by the end of 2020.